Citigroup
HUMA icon

Citigroup’s Humacyte HUMA Stock Holding History

Citigroup’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.82K Sell
6,178
-4,871
-44% -$4.51K ﹤0.01% 5313
2026
Q1 		$6.7K Buy
11,049
+2,276
+26% +$2.37K ﹤0.01% 5178
2025
Q4 		$8.43K Sell
8,773
-326
-4% -$462 ﹤0.01% 5111
2025
Q3 		$15.8K Sell
9,099
-73,438
-89% -$144K ﹤0.01% 4887
2025
Q2 		$173K Sell
82,537
-131,706
-61% -$253K ﹤0.01% 4136
2025
Q1 		$365K Buy
214,243
+42,377
+25% +$159K ﹤0.01% 3840
2024
Q4 		$868K Buy
171,866
+106,249
+162% +$526K ﹤0.01% 3462
2024
Q3 		$357K Buy
65,617
+34,196
+109% +$225K ﹤0.01% 3952
2024
Q2 		$151K Buy
31,421
+20,690
+193% +$108K ﹤0.01% 4020
2024
Q1 		$33.4K Buy
10,731
+154
+1% +$518 ﹤0.01% 4837
2023
Q4 		$30K Buy
10,577
+9,262
+704% +$23.8K ﹤0.01% 4806
2023
Q3 		$3.85K Sell
1,315
-18,675
-93% -$61.8K ﹤0.01% 4788
2023
Q2 		$57.2K Buy
19,990
+18,815
+1,601% +$67.8K ﹤0.01% 4563
2023
Q1 		$3.63K Sell
1,175
-2,197
-65% -$6.25K ﹤0.01% 5006
2022
Q4 		$7.12K Buy
3,372
+234
+7% +$710 ﹤0.01% 4954
2022
Q3 		$10K Sell
3,138
-1,049
-25% -$4.02K ﹤0.01% 4989
2022
Q2 		$13K Sell
4,187
-7,672
-65% -$42.7K ﹤0.01% 5232
2022
Q1 		$84K Buy
11,859
+7,793
+192% +$45.4K ﹤0.01% 4499
2021
Q4 		$29K Buy
4,066
+4
+0.1% +$40 ﹤0.01% 5279
2021
Q3 		$47K Buy
+4,062
New +$46.5K ﹤0.01% 4764

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citigroup's HUMA Position: Q2 2026 in Review

Citigroup reduced its Humacyte (HUMA) stake by 44% in Q2 2026, selling an estimated $4.51K and leaving 6,178 shares worth $4.82K. The position accounts for ﹤0.01% of the portfolio, ranked #5313.

Citigroup first reported a position in HUMA in Q3 2021 and has held it in 20 quarters since. The position peaked at $868K in Q4 2024. 163 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Citigroup held 6,178 shares of Humacyte worth $4.82K as of Q2 2026.
  • Citigroup sold 4,871 Humacyte shares in Q2 2026, an estimated $4.51K.
  • Humacyte made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5313 holding.
  • Citigroup first reported a position in Humacyte in Q3 2021 and has held it in 20 quarters since.
  • Citigroup's Humacyte position peaked at $868K in Q4 2024.
  • 163 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.